TBH Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Free Cash Flow StrengthRobust and improving operating cash flow and strong TTM free cash flow provide durable internal funding. This supports debt paydowns, the $1B buyback plan, and continued R&D investment even if reported earnings remain volatile, improving long-term financial flexibility.
OEM Divestiture Improved Capital FlexibilityThe $1.5B divestiture meaningfully reshapes the capital structure by enabling large debt reduction and funding share repurchases. This structural action lowers interest burden, shortens near-term refinancing risk, and reallocates resources to core franchises and execution priorities over coming years.
Pipeline And R&D MomentumElevated R&D spend and regulatory milestones (EZPLAZ approval; advancing Freesolve trials) strengthen product differentiation in emergency and interventional care. Durable innovation capability supports future procedure-driven recurring revenues and higher-margin specialty offerings over multiple years.
Bears Say
Deteriorated ProfitabilityA shift to large net losses and sharply negative returns undermines earnings power and ROI. Persistent negative margins can erode equity returns, restrict reinvestment capacity, and mean management must rely on one-time actions or cash buffers rather than sustainable operating improvement.
Interventional Integration DelaysExtended order-to-cash, distributor and sales-force integration delays risk prolonging revenue disruption and inflate stranded costs. Slower commercial assimilation of an acquired business can depress medium-term top-line growth and postpone expected synergies and margin recovery.
Margin Pressure From Tariffs And Acquisition MixMaterial margin compression from tariffs and the lower-margin acquisition mix weakens operating leverage. If sustained, this reduces cash conversion and free margin available for debt reduction or R&D, forcing difficult trade-offs and prolonging the time to reach management's steady‑state margin target.
Teleflex News
TBH FAQ
What was Teleflex’s price range in the past 12 months?
Currently, no data Available
What is Teleflex’s market cap?
Teleflex’s market cap is CHF4.58B.
When is Teleflex’s upcoming earnings report date?
Teleflex’s upcoming earnings report date is Oct 22, 2026 which is in 64 days.
How were Teleflex’s earnings last quarter?
Teleflex released its earnings results on Aug 06, 2026. The company reported $1.432 earnings per share for the quarter, beating the consensus estimate of $1.042 by $0.39.
Is Teleflex overvalued?
According to Wall Street analysts Teleflex’s price is currently Undervalued.
Does Teleflex pay dividends?
Teleflex does not currently pay dividends.
What is Teleflex’s EPS estimate?
Teleflex’s EPS estimate is 1.55.
How many shares outstanding does Teleflex have?
Currently, no data Available
What happened to Teleflex’s price movement after its last earnings report?
Teleflex reported an EPS of $1.432 in its last earnings report, beating expectations of $1.042. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Teleflex?
Currently, no hedge funds are holding shares in CH:TBH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teleflex Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF126.82 (― Upside)
CHF126.82 (― Upside)
Blogger Sentiment
Bullish
CH:TBH Sentiment 67%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.98%
Trailing 12-Months
Company Description
Teleflex
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
TBH Company Deck
TBH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic outlook: management reported a quarter that beat on revenue, margin and EPS expectations, closed a sizable OEM divestiture generating ~$1.5B of proceeds to accelerate debt paydown and share repurchases, and highlighted meaningful innovation and R&D progress (EZPLAZ approval, Freesolve milestones). However, the company is navigating near-term headwinds — primarily slower-than-expected integration of the VI acquisition that pressured Interventional revenue, margin compression from tariffs and acquisition mix, stranded costs and regulatory timing on remaining divestitures. Management reiterated a clear plan to reduce debt, return capital, increase R&D focus and deliver margin improvement in 2027, and raised FY EPS guidance while trimming FY revenue growth guidance. On balance, the positive strategic moves, capital returns and innovation progress outweigh the transient integration and margin challenges, with improved financial profile expected in 2027.View all CH:TBH earnings summariesTBH Stock 12 Month Forecast
Average Price Target
―Haemonetics
―
ICU Medical
―
Lemaitre Vascular
―
Merit Medical Systems
―
Bausch + Lomb Corporation
―